Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02101008 | Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy | completed | Phase 2 | 12 | University of UtahOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT02697630 | Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye(PEMDAC) | completed | Phase 2 | 29 | Vastra Gotaland RegionOTHER_GOV | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02223819 | Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy | completed | Phase 2 | 34 | Columbia UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06152367 | Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients | completed | Phase 1 / Phase 2 | 90 | University of ChileOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT02799901 | Nivolumab Plus Radiotherapy in Advanced Melanoma(NIRVANA) | completed | Phase 2 | 72 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT03089606 | Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker | completed | Phase 2 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02407171 | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | completed | Phase 1 / Phase 2 | 61 | Yale UniversityOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT04059224 | TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma(TraMel-WT) | completed | Phase 2 | 45 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02403778 | Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | completed | Phase 2 | 10 | University of Colorado, DenverOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT02515227 | Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab(Mel64) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT01152788 | Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma | completed | Phase 2 | 64 | NCIC Clinical Trials GroupNETWORK | 2 | Aug 22, 2023 | clinicaltrials |
| NCT00336986 | Efficacy Study of IL-21 to Treat Metastatic Melanoma | completed | Phase 2 | 54 | Novo Nordisk A/SINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00053781 | Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma | completed | Phase 2 | 18 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00514085 | Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma | completed | Phase 2 | 40 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT00591370 | Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | completed | Phase 2 | 121 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2023 | clinicaltrials |
| NCT00700882 | Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 81 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT00049530 | PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 32 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00071981 | Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 175 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT00003308 | Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 22, 2023 | clinicaltrials |
| NCT00003601 | Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome | completed | Phase 2 | 38 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03973151 | Study of HL-085 in NRAS Mutant Advanced Melanoma | completed | Phase 1 / Phase 2 | 42 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05217303 | HL-085 in NRAS-mutated Advanced Melanoma | completed | Phase 2 | 100 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT01502293 | Trial of pIL-12 Electroporation Malignant Melanoma(IL-12MEL) | completed | Phase 2 | 51 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03171064 | Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment(Sportivumab) | completed | Phase 2 | 39 | University Hospital HeidelbergOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT02570308 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | completed | Phase 1 / Phase 2 | 146 | Immunocore LtdINDUSTRY | 5 | Mar 21, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT01993719 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02821182 | A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma. | completed | Phase 2 | 20 | University Hospital, GhentOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02731729 | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | completed | Phase 2 | 20 | Parker Institute for Cancer ImmunotherapyOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02038348 | Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study | completed | Phase 2 | 5 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01807182 | Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02115139 | GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases(GRAY-B) | completed | Phase 2 | 58 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT00518206 | Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | completed | Phase 2 | 46 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT00520299 | Study of ADI-PEG 20 in Patients With Advanced Melanoma | completed | Phase 1 / Phase 2 | 31 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03396952 | Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma | completed | Phase 2 | 27 | University of California, San FranciscoOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT00199901 | Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | completed | Phase 2 | 111 | Ludwig Institute for Cancer ResearchOTHER | 3 | Oct 12, 2022 | clinicaltrials |
| NCT00679289 | Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | completed | Phase 2 | 36 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04172454 | Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03834623 | Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02334735 | A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence | completed | Phase 2 | 36 | Nina BhardwajOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT02089685 | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | completed | Phase 1 / Phase 2 | 295 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT01835145 | Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Dec 13, 2023source: clinicaltrials